Bilir, CemilYıldız, İbrahimBilici, AhmetUçar, MahmutBerk, VeliYıldız, YaşarYazıcı, Ozanİnanç İmamoğlu, GökşenKaradurmuş, NuriPilancı, Kezban NurArpacı, ErkanTanrıverdi, ÖzgürKarcı, EbruTemiz, SüleymanNayır, ErdinçOktay, EsinDal, PınarPetekkaya, İbrahimVarım, CeyhunCinemre, Hakan10.07.20192019-07-1010.07.20192019-07-102017Bilir, C., Yıldız, İ., Bilici, A., Uçar, M., Berk, V., Yıldız, Y. ... Cinemre, H. (2017). Is change in hemoglobin level a predictive biomarker of tyrosine kinase efficacy in metastatic renal cell carcinoma? A Turkish oncology group study. Cancer Investigation, 35(4), 248-255. https://dx.doi.org/10.1080/07357907.2017.12925180735-79071532-4192https://dx.doi.org/10.1080/07357907.2017.1292518https://hdl.handle.net/20.500.12511/2119WOS: 000399505100004PubMed ID: 28333566Background: There are insufficient predictive markers for renal cell carcinoma (RCC). Methods: A total of 308 metastatic RCC patients were analyzed retrospectively. Results: The increased hemoglobin (Hb) group had significantly higher progression-free survival and overall survival (OS) compared with the decreased Hb group at 11.5 versus 6.35months (p < .001) and 21.0 versus 11.36months (p < .001) respectively. The 1- and 3-year OS rates were higher in the Hb increased group, i.e., 84% versus 64% and 52% versus 35% respectively. Conclusions: The present study showed that increased Hb levels after tyrosine kinase inhibitor therapy could be a predictive marker of RCC.eninfo:eu-repo/semantics/embargoedAccessHemoglobinPredictiveRenal Cell CarcinomaSurvivalTyrosine Kinase InhibitorArticle35424825510.1080/07357907.2017.1292518Q4Q2